Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2025-01-01
DOI
https://doi.org/10.1093/noajnl/vdaf101
Citations
2
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm

Andrea M. Gross, Eva Dombi, Kyaw Sint, Brigitte C. Widemann et al.
2 citations
Neuro-Oncology Advances
Neurofibromatosis and Schwannoma Cases
2.78
article

Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm

Andrea M. Gross, Eva Dombi, Kyaw Sint, Brigitte C. Widemann, Ayoade Adeyemi, Andrea Baldwin
article en
2 citations

Abstract

No abstract available for this paper.
Neuro-Oncology AdvancesVol. 7(1)
AstraZeneca (Brazil) (BR), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (US)
Good health and well-being
Openalex Percentile: Top 10%
Neurofibromatosis and Schwannoma Cases
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.